Longevity senotherapeutics report: TAmiRNA

Biomarkers for more stability in life – TAmiRNA is harnessing the power of microRNAs for the development of innovative diagnostic tools.

Over the coming weeks, we will be bringing you extracts from 7 company profiles from our Longevity Senotherapeutics Report. Each profile includes an assessment of Longevity Potential, Pre-Clinical and Clinical Studies, Technology/platform analysis, Safety and Risks, Target Market and Success Factors.

We also study each company’s IP, team, UVP, product efficacy, competitive advantage, runway and inflection point, and much more. Here’s the lowdown on TAmiRNA.

To view a full size version of TAmiRNA’s profile please click here.

TAmiRNA is a Biotech company which was founded in 2013 as a spin-off from the University of Natural Resources and Life Sciences Vienna (BOKU). TAmiRNA conducts research and development of microRNA-based diagnostic tests for several age-associated diseases including senescence-associated diseases (senomiR®), osteoporosis (osteomiR®), cardiovascular disease (thrombomiR®), and liver diseases (hepatomiR®).

In addition, TAmiRNA serves as a CRO by providing R&D teams at universities and companies with RNA biomarker solutions for drug safety assessments (toxomiR®), as well as compelling solutions for the analysis of non-coding RNAs in biofluids, single-cells or tissue compartments in any research area. Utilising microRNAs as diagnostic and prognostic biomarkers for senescent burden offers unique opportunities to address many of the issues currently present in the field. This includes (but is not limited to) minimally invasive access to biomarker samples, aiding in resolving senescent cell heterogeneity and high translatability.

TAmiRNA’s overall mission is to develop novel diagnostic solutions for unmet clinical needs and to offer high-quality analytical services in compliance with the high standards required by diagnostics development. Through doing this, they hope to prolong the stability, health and quality of life of individuals as they age.

Matthias Hackl, CEO and Co-founder

At launch, the team (consisting of Matthias Hackl, Regina Grillari, Johannes Grillari and Otto Kanzler) had acquired compelling data in relation to secretory microRNA profiles of senescent cells. “The observation that senescent cells could exert a paracrine effect through release of specific microRNAs into the circulation showed us the huge potential of cell-free microRNAs as biomarkers of senescence, aging and age-related diseases.” Shortly after patenting and publishing the data on cross-talk between senescence-associated microRNAs and bone-formation, TAmiRNA was founded to explore the use of microRNAs as osteoporosis biomarkers (osteomiR®) and subsequently also CVD, liver disease and senescence.

TAmiRNA collaborates with expert biostatisticians, bioinformaticians and epidemiologists in order to identify and validate microRNA biomarkers for diagnosis, prognosis, treatment monitoring and drug development. In this way TAmiRNA uses the full resources and expertise of its team to harness the power of microRNAs to create innovative tools that will drive the longevity field forward. The COVID pandemic has revealed the pervasive role and potential impact that RNA base innovations can have on our health and wellness, particularly in regard to disease prevention.

Our world is rapidly changing, as is the rate of scientific and technological progress. In order to rapidly diagnose the diseases associated with an increased death rate, new and improved methods are necessary. MiRNAs have the required properties to constitute such a method. Through developing next generation technologies and talent, TAmiRNA is dedicated to constant growth and improvements in order to maintain its competitive advantage in this field.


To date, TAmiRNA has completed and patented the development of a transcriptomic landscape of cellular senescence. The company plans to continuously expand its senescence microRNA biomarker panel (through preclinical R&D efforts) with cell-type specific biomarkers based on newly generated data. TAmiRNA recognises that the development of accurate diagnostic and prognostic tests for senescence in humans is one of the major hurdles standing in the way of clinical trial success. Hence, it is focused on continuously engaging in partnerships with companies that are developing and validating their novel senotherapeutics. TAmiRNA recognises high potential for mergers or acquisitions of their development projects in the next 3-7 years.

Access to the report can be found HERE, and check out our other senotherapeutic company profiles HERE.

Images courtesy of TAmiRNA